Schering-Plough, PTC to collaborate
Schering-Plough will pay $12 million down and up to $200 million after factoring in potential milestone payments for the rights to develop PTC Therapeutics' preclinical therapies for hepatitis C and other viral diseases. Schering-Plough will also provide research funds to PTC. PTC's small molecules are designed to inhibit the production of viral proteins involved in replication of the hepatitis C virus.
"Schering-Plough's expertise in the research and development of antiviral therapies and its global hepatitis franchise affords PTC the opportunity to realize the full potential of our IRES inhibitors," said Stuart Peltz, president & CEO of PTC Therapeutics. "This collaboration provides additional validation for the GEMS technology and nicely complements our strategy as we advance internally the development of our clinical programs."
- here's the press release for more
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
